Description
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
Please contact Poornima Murali to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
-
California
- USC/Kenneth Norris Comprehensive Cancer Center Oncology Dept, Los Angeles, California, 90033
- Stanford University Medical Center Oncology Dept, Stanford, California, 94304
-
New Mexico
- New Mexico Cancer Care Alliance Oncology Dept, Albuquerque, New Mexico, 87106
-
Washington
- Swedish Cancer Institute Onc Dept, Seattle, Washington, 98104
-
Minnesota
- Mayo Clinic - Rochester Onc Department, Rochester, Minnesota, 55905
-
Indiana
- Indiana University Health Goshen Center for Cancer Oncology Department, Indianapolis, Indiana, 46202
-
France
- Novartis Investigative Site, Villejuif Cedex, 94805
Powered by
SC CTSI